Biotricity Reinforces Growth Trajectory, Kicking Off Fiscal 2026 with Strong First Quarter Results Featuring Revenue Growth, Positive EBITDA and Improved Margins
Biotricity (OTCQB:BTCY) reported strong Q1 FY2026 results, marking a significant milestone with its first-ever positive EBITDA of $333,337. Revenue grew 21% to $3.9 million, with recurring Technology-as-a-Service fees increasing 11.8% to $3.4 million. The company achieved an improved gross margin of 80.5%, up from 73.8% year-over-year.
Net loss significantly decreased to $0.75 million ($0.03 per share), an 80.6% improvement from the previous year. The company's strategic expansion now covers 70% of the US market, with partnerships giving access to 90% of all US hospitals. Biotricity's AI-driven Cardiac Cloud platform, leveraging over 2 trillion beats of anonymized data, is advancing towards FDA clearance.
Biotricity (OTCQB:BTCY) ha riportato solidi risultati nel primo trimestre dell'anno fiscale 2026, segnando un traguardo importante con il primo EBITDA positivo di $333,337. I ricavi sono cresciuti del 21% a $3,9 milioni, con i ricavi ricorrenti da Technology-as-a-Service in aumento dell'11,8% a $3,4 milioni. La societ脿 ha registrato un miglioramento del margine lordo, salito al 80,5% rispetto al 73,8% dell'anno precedente.
La perdita netta si 猫 ridotta significativamente a $0,75 milioni ($0,03 per azione), un miglioramento dell'80,6% rispetto all'anno precedente. L'espansione strategica dell'azienda copre ora il 70% del mercato statunitense, con partnership che assicurano l'accesso al 90% di tutti gli ospedali USA. La piattaforma Cardiac Cloud di Biotricity, basata sull'IA e alimentata da oltre 2 trilioni di battiti anonimizzati, si avvia verso l'approvazione FDA.
Biotricity (OTCQB:BTCY) present贸 s贸lidos resultados en el primer trimestre del ejercicio 2026, alcanzando un hito con su primer EBITDA positivo de $333,337. Los ingresos crecieron un 21% hasta $3.9 millones, con las tarifas recurrentes de Technology-as-a-Service aumentando un 11.8% hasta $3.4 millones. La compa帽铆a logr贸 un margen bruto mejorado del 80.5%, frente al 73.8% del a帽o anterior.
La p茅rdida neta se redujo significativamente a $0.75 millones ($0.03 por acci贸n), una mejora del 80.6% respecto al a帽o anterior. La expansi贸n estrat茅gica de la compa帽铆a ahora cubre el 70% del mercado estadounidense, con alianzas que dan acceso al 90% de todos los hospitales de EE. UU. La plataforma Cardiac Cloud impulsada por IA de Biotricity, que aprovecha m谩s de 2 billones de latidos anonimados, avanza hacia la aprobaci贸n de la FDA.
Biotricity (OTCQB:BTCY)電� 2026須岅硠鞐半弰 1攵勱赴 鞁れ爜鞚� 氚滍憸頃橂┌ 觳橃潓鞙茧 $333,337鞚� 頂岆煬鞀� EBITDA毳� 旮半頃橂姅 霌� 瓴“頃� 靹标臣毳� 雰堨姷雼堧嫟. 毵れ稖鞚� 21% 歃濌皜顷� $3.9 million鞚� 旮半頄堦碃, 甑弲順� Technology-as-a-Service 靾橃澋鞚� 11.8% 歃濌皜顷� $3.4 million鞓�鞀惦媹雼�. 須岇偓鞚� 毵れ稖齑濎澊鞚惦鞚� 鞝勲厔鞚� 73.8%鞐愳劀 臧滌劆霅橃柎 80.5%毳� 旮半頄堨姷雼堧嫟.
靾滌啇鞁れ潃 韥矊 欷勳柎 $0.75 million(欤茧嫻 $0.03)鞚� 霅橃棃鞙茧┌, 鞝勲厔 雽�牍� 80.6% 臧滌劆霅橃棃鞀惦媹雼�. 鞝勲灥鞝� 頇曥灔鞙茧 氙戈淡 鞁滌灔鞚� 70%毳� 旎る矂頃橁矊 霅橃棃瓿�, 韺岉姼雱堨嫮鞚� 韱淀暣 氙戈淡 雮� 鞝勳泊 氤戩洂鞚� 90%鞐� 鞝戧芳頃� 靾� 鞛堦矊 霅橃棃鞀惦媹雼�. Biotricity鞚� AI 旮半皹 Cardiac Cloud 頂岆灚韽检潃 鞚惦獏頇旊悳 2臁� 瓯� 鞚挫儊鞚� 鞁灔 氚曤彊 雿办澊韯半ゼ 頇滌毄頃橂┌ FDA 鞀轨澑 鞝堨皑毳� 頄ロ暣 雮橃晞臧�瓿� 鞛堨姷雼堧嫟.
Biotricity (OTCQB:BTCY) a publi茅 de solides r茅sultats pour le premier trimestre de l'exercice 2026, franchissant une 茅tape importante avec son premier EBITDA positif de 333 337 $. Le chiffre d'affaires a augment茅 de 21% 脿 3,9 millions $, les revenus r茅currents de Technology-as-a-Service progressant de 11,8% 脿 3,4 millions $. La marge brute s'est am茅lior茅e 脿 80,5%, contre 73,8% un an plus t么t.
La perte nette a 茅t茅 r茅duite de mani猫re significative 脿 0,75 million $ (0,03 $ par action), soit une am茅lioration de 80,6% par rapport 脿 l'ann茅e pr茅c茅dente. L'expansion strat茅gique couvre d茅sormais 70% du march茅 am茅ricain, des partenariats offrant un acc猫s 脿 90% de l'ensemble des h么pitaux aux 脡tats-Unis. La plateforme Cardiac Cloud de Biotricity, aliment茅e par l'IA et exploitant plus de 2 000 milliards de battements anonymis茅s, progresse vers l'homologation par la FDA.
Biotricity (OTCQB:BTCY) meldete starke Ergebnisse f眉r das erste Quartal des Gesch盲ftsjahres 2026 und erreichte mit einem erstmals positiven EBITDA von $333,337 einen wichtigen Meilenstein. Der Umsatz stieg um 21% auf $3,9 Millionen, wobei die wiederkehrenden Technology-as-a-Service-Einnahmen um 11,8% auf $3,4 Millionen zunahmen. Die Bruttomarge verbesserte sich auf 80,5% 驳别驳别苍眉产别谤 73,8% im Vorjahr.
Der Nettoverlust verringerte sich deutlich auf $0,75 Millionen ($0,03 je Aktie), eine Verbesserung von 80,6% 驳别驳别苍眉产别谤 dem Vorjahr. Die strategische Expansion deckt nun 70% des US-Marktes ab, Partnerschaften verschaffen Zugang zu 90% aller Krankenh盲user in den USA. Biotricitys KI-gest眉tzte Cardiac Cloud-Plattform, die auf mehr als 2 Billionen anonymisierten Herzschl盲gen basiert, r眉ckt n盲her an die FDA-Zulassung.
- First-ever positive EBITDA of $333,337, marking transition to operational profitability
- Revenue growth of 21% to $3.9 million in Q1 FY2026
- Significant gross margin improvement to 80.5% from 73.8% year-over-year
- Net loss reduced by 80.6% to $0.75 million
- Strategic partnerships secured with access to 90% of US hospitals
- Strong recurring revenue with TaaS fees up 11.8% to $3.4 million
- Geographic expansion across 70% of US market
- Company still operating at a net loss of $0.75 million
- International expansion still pending regulatory approvals
- AI clinical model still awaiting FDA clearance
Insights
Biotricity achieves positive EBITDA milestone with 21% revenue growth and substantially reduced losses, signaling sustainable business model emergence.
Biotricity's Q1 fiscal 2026 results mark a pivotal transformation from startup to sustainable business model. The company reported
The company's gross margin expanded significantly to
Net losses decreased substantially to
Strategic partnerships with three major Group Purchasing Organizations (GPOs) have opened access to approximately
REDWOOD CITY, CA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company鈥�), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, today announced its financial results for its first quarter of fiscal 2026, ended June 30, 2025. Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, "We鈥檙e proud to deliver another quarter of strong performance and a shift to positive EBITDA, which demonstrates the scalability of our business model and strength of our team. Management believes that this a foundational milestone for Biotricity, exemplifying our ability to grow our business as we go from a loss-producing startup to a business that can operate profitably. Following a massive year of positive transformation for Biotricity, we continue to harness the power of workflow automation, AI technology, and other technological enhancements to further improve our operational expenses, margins, and revenues. This powerful combination has set the foundation to fuel ongoing growth. In doing so, we demonstrate our ability to scale with strategic focus and long-term sustainability. The expansion of our Cardiac AI Cloud platform, empowered by strategic partnerships with industry giants, showcases our commitment to revolutionizing medical diagnostics and consumer healthcare. Leveraging over 2 trillion beats of anonymized data, our AI-driven platform is set to enhance clinic profitability, paving the way for transformative advancements in diagnostic accuracy and patient outcomes. Importantly, we remain on track to pursue FDA clearance for our groundbreaking AI clinical model in the coming months.
Strategic alliances forged during fiscal 2025 and 2026 have positioned us to capitalize on expansive market channels, providing access to approximately
Q1-FY26 Financial Highlights
- Revenue increased
21% to$3.9 million , compared with$3.2 million in Q4 FY24 - Gross margin was
80.5% for the three months ended June 30, 2025, as compared to73.8% in the corresponding prior year quarter; this is the result of expansion in the recurring technology fee revenue base, efficiencies gained in using proprietary AI in operational automation, and improvement in monitoring and cloud cost structure. - Net loss decreased to
$0.75 million , or$0.03 per share, from a net loss of$6.9 million , or$0.49 per share, in Q1-FY25; this was an80.6% improvement even after removing the effects of a$3 million one-time deemed dividend in the corresponding prior year period. - Positive EBITDA of
$333,337 , first time in the Company鈥檚 history; EBITDA increased by118.7% compared to corresponding prior year quarter; this is the result of growth and operating efficiencies.
Operating Highlights for Q1-FY26 and the Future
- Q1-FY26 recurring (TaaS) Technology Fees rose a robust
11.8% from the corresponding period of the prior year, to$3.4 million , which is also7.9% increase from the immediately preceding three-month period. - Company maintained its track record of strong customer retention, supported by the quality of customer and physician-friendly support services which emphasize the accuracy of our diagnostics and ease-of-use of our solution.
- Leveraging on its adept development of a range of state-of-the-art products to service a total addressable market of
$35 billion . - Working on achieving regulatory approval in internation markets, with a view to laying the foundation for distribution in those markets in the coming years, after successfully achieving approvals in Canada, Saudi Arabia and Argentina.
- Expansion of geographic footprint across
70% of the US, with penetration across thousands of physicians over hundreds of centers, including those acquired through relationships with strategic partners. - Secured strategic alliances with three of the top GPOs representing
90% of all hospitals in the US.
Full details of the Company's financial results will be filed with the SEC on Form 10-Q and available by visiting .
Financial Results and Business Update Conference Call
Management will host a conference call on Thursday August 14, 2025 at 4:30 p.m. ET to discuss its financial results for fiscal first quarter of 2026 and provide a business update. Additional details are available under the Investor Relations section of the Company's website:
Event: Biotricity First Quarter Fiscal 2026 Financial Results and Business Update Call
Date: Thursday, August 14, 2025
Time: 4:30pm ET (1:30pm PT)
Toll Free: 1-877-269-7751
International: 1-201-389-0908
Webcast URL:听
Investors can begin accessing the webcast 15 minutes before the call, where an operator will register your name and organization. The call will be in listen-only mode.
A replay of the call will be available approximately three hours after the live call via the Investors section of the Biotricity website at .
Toll Free Replay Number: 1-844-512-2921
International: 1-412-317-6671
Replay Access ID: 13755374
Expiration: Thursday, August 28, 2025听at 11:59 PM ET
About Biotricity Inc.
Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity's unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The Company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit .
Non-GAAP Measures
Non-GAAP financial information presented may be determined or calculated differently by other companies and may not be directly comparable to that of other companies. It is management鈥檚 intent to provide non-GAAP financial information to enhance the understanding of Biotricity鈥檚 GAAP financial information, and it should be considered by the reader in addition to, but not instead of, the financial statements prepared in accordance with GAAP. We believe that providing these non-GAAP measures in addition to the GAAP measures allows management, investors and other users of our financial information to more fully and accurately assess business performance. Earnings before interest, tax, depreciation and amortization (鈥淓BITDA鈥�) is one such measure:
| 听 | 听 | 听 | 3 months ended June 30, 2025 | 听 | 听 | 3 months ended June 30, 2024 | 听 | |||
| 听 | 听 | 听 | $ | 听 | 听 | $ | 听 | |||
| Net loss attributable to common stockholders | 听 | 听 | 听 | (754,293 | ) | 听 | 听 | (6,948,292 | ) | 听 |
| Add: | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | |
| Provision for income taxes | 听 | 听 | 听 | - | 听 | 听 | 听 | - | 听 | 听 |
| Interest expense | 听 | 听 | 听 | 850,254 | 听 | 听 | 听 | 768,673 | 听 | 听 |
| Accretion and amortization expenses | 听 | 听 | 听 | 153,572 | 听 | 听 | 听 | 1,144,728 | 听 | 听 |
| Depreciation | 听 | 听 | 听 | 1,488 | 听 | 听 | 听 | 1,488 | 听 | 听 |
| Preferred stock dividends | 听 | 听 | 听 | 82,316 | 听 | 听 | 听 | 3,253,772 | 听 | 听 |
| EBITDA | 听 | 听 | 听 | 333,337 | 听 | 听 | 听 | (1,779,631 | ) | 听 |
| Weighted average number of common shares outstanding | 听 | 听 | 听 | 26,284,734 | 听 | 听 | 听 | 14,169,441 | 听 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | |
| Profit (Loss) per Share, Basic and Diluted | 听 | 听 | 听 | 0.013 | 听 | 听 | 听 | (0.126 | ) | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," "project," or "goal" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company's other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Contacts
Investor Relations
Biotricity Investor Relations
SOURCE: Biotricity Inc.
FAQ
What were Biotricity's (BTCY) Q1 2026 earnings results?
What is Biotricity's (BTCY) current gross margin?
How much recurring revenue does Biotricity (BTCY) generate?
What is Biotricity's (BTCY) market presence in the US?
What progress has Biotricity (BTCY) made with its AI technology?
